Senores Pharmaceuticals Intrinsic Value
Senores Pharmaceuticals (SENORES) median intrinsic value is ₹404.17 from 8 valuation models (range ₹275–₹576), vs current price ₹916.70 — -55.9% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Senores Pharmaceuticals share price today.
SENORES Valuation Methods Summary — DCF, Graham Number & P/E
Senores Pharmaceuticals intrinsic value across 8 models vs current price ₹916.70 — upside/downside and value range per method. Browse SENORES quarterly financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹575.52 | ₹460.42 - ₹690.62 | -37.2% | EPS: ₹26.16, Sector P/E: 22x |
| Book Value Method | asset | ₹353.04 | ₹317.74 - ₹388.34 | -61.5% | Book Value/Share: ₹176.52, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹276.52 | ₹248.87 - ₹304.17 | -69.8% | Revenue/Share: ₹138.26, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹408.70 | ₹367.83 - ₹449.57 | -55.4% | EBITDA: ₹188.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹275.01 | ₹247.51 - ₹302.51 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹404.17 | ₹363.75 - ₹444.59 | -55.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹458.35 | ₹412.52 - ₹504.19 | -50.0% | ROE: 14.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹322.34 | ₹290.11 - ₹354.57 | -64.8% | EPS: ₹26.16, BVPS: ₹176.52 |
SENORES Intrinsic Value vs Market Price — All Valuation Models
Senores Pharmaceuticals fair value range ₹275–₹576 vs current market price ₹916.70 across 8 valuation models. Compare with SENORES fair price to assess whether the stock is under or overvalued.
SENORES Intrinsic Value Analysis — Undervalued or Overvalued?
Senores Pharmaceuticals median intrinsic value ₹404.17, current price ₹916.70 — Trading Above Calculated Value by 55.9%, margin of safety -100.0%.
What is the intrinsic value of SENORES?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Senores Pharmaceuticals (SENORES) is ₹404.17 (median value). With the current market price of ₹916.70, this represents a -55.9% variance from our estimated fair value.
The valuation range spans from ₹275.01 to ₹575.52, indicating ₹275.01 - ₹575.52.
Is SENORES undervalued or overvalued?
Based on our multi-method analysis, Senores Pharmaceuticals (SENORES) appears to be trading above calculated value by approximately 55.9%.
SENORES Financial Health — Key Ratios vs Industry Benchmarks
Senores Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.15 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.52x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SENORES Cash Flow Quality — Operating & Free Cash Flow
Senores Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-46 Cr | ₹-261 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-26 Cr | ₹-53 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-25 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-10 Cr | ₹-22 Cr | Negative Cash Flow | 3/10 |